Septerna (NASDAQ:SEPN) SVP Daniel Long Sells 3,334 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,334 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total transaction of $114,922.98. Following the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at approximately $3,323,321.64. This trade represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Septerna Price Performance

Septerna stock opened at $38.76 on Thursday. Septerna, Inc. has a 1 year low of $10.62 and a 1 year high of $40.63. The firm’s 50 day moving average price is $34.06 and its 200-day moving average price is $28.83. The stock has a market cap of $1.75 billion, a P/E ratio of -47.85 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. The firm had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, equities analysts expect that Septerna, Inc. will post -1.59 EPS for the current year.

Hedge Funds Weigh In On Septerna

A number of institutional investors and hedge funds have recently made changes to their positions in SEPN. Woodline Partners LP raised its position in shares of Septerna by 94.2% during the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after buying an additional 282,585 shares in the last quarter. Rhumbline Advisers grew its position in Septerna by 16.6% in the first quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after acquiring an additional 3,323 shares in the last quarter. Geode Capital Management LLC grew its position in Septerna by 19.1% in the second quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after acquiring an additional 78,316 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares during the last quarter. Finally, CW Advisors LLC bought a new stake in Septerna during the second quarter worth approximately $133,000.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Raymond James Financial raised their price objective on Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a research report on Monday, June 8th. Guggenheim decreased their target price on Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday, July 1st. Stifel Nicolaus assumed coverage on Septerna in a report on Friday, May 1st. They set a “buy” rating and a $43.00 price target for the company. Truist Financial lifted their price objective on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Septerna presently has an average rating of “Moderate Buy” and a consensus price target of $45.89.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.